Sentences with phrase «defined as a tumor»

Any lump, growth, or swelling on a dog is defined as a tumor.

Not exact matches

Center for Elephant Conservation, elephants have 38 additional modified copies (alleles) of a gene that encodes p53, a well - defined tumor suppressor, as compared to humans, who have only two.

Researchers in Sweden sought to determine if use of tumor necrosis factor inhibitor drugs to treat RA would result in a reduced risk of acute coronary syndrome (commonly called ACS), defined as a diagnosis of a heart attack or unstable angina (the worsening or increasing cardiac symptoms)

Regrowth or progression of tumor was defined as any increase in size of known residual tumor on follow - up radiographic imaging.

In breast cancer, miR - 21, 155, 27, 96, 182, and 128 were identified as oncogenes, whereas miR - 125, 205, 27, 17, 206, and 145 were found to be tumor suppressor genes, and their corresponding target genes were also defined (10 — 12).

As an initial focus, researchers at Chicago will search for novel ways to take advantage of steroid hormones and their receptors to detect metastases, define their boundaries and deliver treatments directly to tumor cells in order to inhibit cell division or promote cell death.

Our findings show how the tumor microenvironment drives the acquisition of CD39 as an immune regulatory molecule on CD8 + T cells, with implications for defining a biomarker of T cell dysfunction and a target for immunotherapeutic intervention.

For more information regarding Bristol - Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: • Early stage IB - IIIA, operable non-small cell lung cancer, confirmed in tissue • Lung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could apply

We need a new type of vaccine that uses select components of a microbe or tumor cell or other cause of disease, and administers these with other defined substances, such as adjuvants, that directly exploit immunology.»

Inclusion Criteria: • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 • Have histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC)(Stage IIIb or greater) • Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 • Known PD - L1 tumor status as determined by an immunohistochemistry (IHC) assay performed by the central laboratory on tissue obtained at Screening • A woman of childbearing potential must have a negative highly sensitive serum (beta - human chorionic gonadotropin [beta - hCG]-RRB- at Screening within 14 days prior to study drug administration Inclusion Criteria for Crossover: • Participants must have been randomized to Arm A of the study and had radiographic disease progression according to RECIST 1.1 • Participants must have a mandatory biopsy at the time of disease progression according to RECIST 1.1 prior to crossing over.

The company showed how they first defined A2A as the receptor required for mediating the effect of adenosine on immune cells within the tumor microenvironment and reported the characterization of a novel immuno - oncology - dedicated adenosine receptor 2A antagonist that functions in the high adenosine concentration found in tumors.

Two tumors (4 %) had a partial response, defined as reduction in tumor volume of more than 30 percent.

Death caused by leukemia was defined by enlargement of the spleen and liver on autopsy, whereas death caused by GVHD was defined as the absence of tumor and the presence of GVHD.

The laboratory currently pursues four integrated research objectives: 1) Defining how dynamic regulation of adhesion and migration controls metastasis, 2) Identification and characterization of the metastatic cell populations within a primary tumor, 3) Experimental modeling of metastasis in a clinically relevant manner, and 4) clinical implementation of molecular markers of migration as biomarkers of tumor progression and metastasis.

It is defined as a decrease of ≥ 50 % in the total tumor size and / or total number of tumors since the start of the trial.

It is defined as the complete disappearance of all tumors identified at the beginning of the trial, as well as any new tumors.

It is defined as an increase of ≥ 25 % in total tumor size and / or number of tumors since the start of the trial.

These results define PGBD5 as an oncogenic mutator and provide a plausible mechanism for site - specific DNA rearrangements in childhood and adult solid tumors.

Areas of focus include: understanding how tumour - reactive T cells and B cells promote patient survival in cancer; defining the effects of standard treatments on tumor immunity; and using genomic approaches to identify novel tumour mutations that can serve as target antigens for immunotherapy.

They're designing drugs now that are blocking mTOR, and they define it as molecule that helps drive the growth of many tumors.

Typically, the cells of benign and malignant mesenchymal tumors have poorly - defined cell membranes as compared to epithelial tumors.

Choroid plexus tumors are seen as well - defined, hyperdense masses with marked, uniform contrast enhancement on CT scans.